Overview

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

Status:
Not yet recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome

Phase:

Phase 2

Details

Lead Sponsor:

Neuren Pharmaceuticals Limited